COLELLA, ELISA
COLELLA, ELISA
Universita' degli Studi di MILANO
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting
2021 M. Fabbiani, A. Lombardi, M. Colaneri, P. Del Poggio, P. Perini, R. D'Ambrosio, E. Degasperi, C. Dibenedetto, A. Giorgini, L. Pasulo, F. Maggiolo, F. Castelli, P. Brambilla, O. Spinelli, T. Re, A. Lleo, M. Rumi, C. Uberti-Foppa, A. Soria, A. Aghemo, P. Lampertico, C. Baiguera, M. Schiavini, S. Fagiuoli, R. Bruno, M. Borghi, R. Soffredini, R. Perbellini, A. Gori, V. Ferroni, M. Colpani, M. Manini, G. Cologni, S. Lazzaroni, M. Vinci, S. De Nicola, C. Mazzarelli, T. Angelini Zucchetti, V. Picciotto, M. Puoti, R. Rossotti, S. Landonio, C.F. Magni, G. Rizzardini, E. Colella, P. Columpsi, A. Gambaro, A. Spolti, C. Magnani, P. Vigano, M. Mena, M. Villa, I. Caramma, C. Basilico, F. Capelli, S. Biagiotti, A. Mazzone, V. Saladino, M.P. Baldacci, F. Gatti, L. Varalli, L. Morini, B. Menzaghi, M. Farinazzo, R. Meli, M.C. Plaz Torres, M. Rumi, I. Fanetti, C. Dibenedetto, D. Orellana, P. Zermiani, M. Zuin, A. De Bona, A. D'Arminio Monforte, A. Capretti, M.T. Taddei, M. Soncini, A. Spinetti, S. Zaltron, M.G. Pigozzi, A. Rossini, A. Pan, S. Dal Zoppo, A. Zoncada, M. Memoli, S. Salpietro, H. Hamid, E. Messina, A.E. Colombo, O. Giglio, P. Bonfanti, C. Molteni, N. Terreni, G. Spinzi, S. Conforti, E. Clerici, F. Menozzi, E. Buscarini, R. Centenaro, A. Corbellini, F. Noventa, S. Gritti, P. Giani
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation
2020 V. Di Cristo, F. Adorni, R. Maserati, M. Annovazzi Lodi, G. Bruno, P. Maggi, A. Volpe, P. Vitiello, C. Abeli, S. Bonora, M. Ferrara, M.V. Cossu, M.L. Oreni, E. Colella, S. Rusconi
Integrase inhibitors use and CMV infection predict immune recovery in peolple living with HIV starting first-line therapy
2020 M. Fabbiani, A. Borghetti, N. Squillace, M. Colafigli, L. Taramasso, A. Lombardi, B. Rossetti, A. Ciccullo, E. Colella, C. Picarelli, M. Berruti, A. Latini, F. Montagnani, M. Sambo, A. Di Biagio, A. Gori, S. Di Giambenedetto, A. Bandera
Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients
2019 M. Fabbiani, N. Ciccarelli, V. Castelli, A. Soria, A. Borghetti, E. Colella, D. Moschese, M. Valsecchi, A. Emiliozzi, A. Gori, A. De Luca, A. Bandera, S. Di Giambenedetto
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
2018 N. Squillace, G. Bozzi, E. Colella, A. Gori, A. Bandera
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial
2018 E. Colella, D. Cattaneo, L. Galli, S. Baldelli, E. Clementi, M. Galli, A. Lazzarin, A. Castagna, S. Rusconi, V. Spagnuolo
The contribution of immune activation and accelerated aging in multiple myeloma occurring in HIV-infected population
2018 A. Bandera, E. Colella, M. Clerici, G. Rizzardini, A. Gori
Factors involved in continuance of atazanavir-based regimens : Results from a cohort of HIV1-positive patients
2016 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, E. Colella, A.L. Ridolfo, M. Galli, S. Rusconi
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy : A postauthorization noninterventional study
2016 A. Antinori, P. Meraviglia, A.D. Monforte, A. Castagna, C. Mussini, T. Bini, N. Gianotti, S. Rusconi, E. Colella, G. Airoldi, D. Mancusi, R. Termini
Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI
2014 G.M. Bottani, M.L. Oreni, G. Orofino, P. Tau, S. Di Nardo Stuppino, E. Colella, S. Carosella, M. Guastavigna, V. Ghisetti, V. Micheli, M. Galli, S. Rusconi
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
2014 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, B. Vergani, M. Morosi, E. Colella, M. Galli, S. Rusconi
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients
2014 S. Bonora, A. Calcagno, O. Vigano, P. Bigliano, L. Marinaro, E. Colella, G. Orofino, L. Trentini, M.C. Tettoni, A. D'Avolio, S. Mercadante, M. Galli, G.D. Perri, S. Rusconi
ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?
2013 L. Milazzo, D. Cattaneo, S. Cheli, L. Ferraris, E. Colella, E.G.I. Clementi, C. Gervasoni
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
2013 S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D'Annunzio, A. Di Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, G. D'Ettorre, D. Francisci, G. Parruti, A. Soria, A.R. Buonomini, C. Tommasi, S. Mosti, F. Bai, S. Di Nardo Stuppino, M. Morosi, M. Montano, P. Tau, E. Merlini, G. Marchetti
Maraviroc : un inibitore del co-recettore CCR5 con un unico profilo di efficacia e tollerabilita’ in diversi scenari clinici dell'infezione da HIV-1
2012 S. Rusconi, E. Colella, P. Vitiello
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients
2012 A. Giacomelli, M. Franzetti, B. Vergani, L. Oreni, M. Morosi, V. Di Cristo, E. Colella, O. Viganò, M. Galli, S. Rusconi
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
2010 S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A.F. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D’Annunzio, A. Di Biagio, A. Di Pietro, L. Butini, G. Orofino, S. Farina, G. D’Ettorre, D. Francisci, A. Soria, A.R. Buonomini, C. Tommasi, M.P. Trotta, M. Capasso, E. Merlini, G.C. Marchetti